纳米图包括 Sarcopenia 预测局部 papillary 细胞癌患者的无进展生存:一个回顾性队列研究
Wenhui Su1, Yukun Wu1, Shufen Liao2
1Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Annals of surgical oncology
|July 2, 2024
概括
这项研究开发了局部 papillary 细胞癌 (pRCC) 患者的预后名录. 诺米图包含了萨尔科佩尼亚,身体组成,瘤直径和手术技术,以预测癌症的进展,帮助预测存活率.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
背景情况:
- 胞性细胞癌 (pRCC) 的分类删除影响了手术后的生存预后.
- 萨科佩尼亚是细胞癌 (RCC) 患者的已知预后因素.
- 身体组成参数需要全面调查以预测局部的pRCC存活率.
研究的目的:
- 调查局部pRCC. 的身体组成参数的生存预测.
- 开发一种预后模型,用于预测局部PRCC患者的无进展生存率.
主要方法:
- 对105名局部化pRCC患者的回顾性分析.
- 从手术前CT扫描中测量骨肌肉指数 (SMI),皮下脂肪组织 (SAT) 和围脂肪组织 (PRAT).
- 使用考克斯回归分析开发预后名录,并通过C指数和ROC曲线进行验证.
主要成果:
- 在74.29%的患者中存在类.
- 多变量分析确定了sarcopenia,SAT,PRAT,瘤直径和手术技术作为进展的独立风险因素.
- 开发的预后名录显示出良好的预测性能,C指数为0.831.
结论:
- 一个综合萨尔科佩尼亚,SAT,PRAT,瘤直径和外科手术技术的预后诺莫грам可以预测局部pRCC的进展.
- 这种名谱有助于对局部PRCC患者的生存预后.
- 临床实施需要进一步的外部验证.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342


